✦   ✦   ✦

breaking news

News, read through The Primal Race
← 全部评论 · all commentary

别被“温柔”的词汇骗了,这才是真正的结构性胜利Don't be Fooled by 'Kindness': This is a Structural Victory

好消息 结构层 · 文化层 The Guardian ↗ 2026-06-02 § 链接
好新闻不看氛围,看 Actual 是否向 Potential 靠近。
Good news isn't about vibes; it's about Actual moving closer to Potential.

很多医疗新闻喜欢用“kinder”或“life-changing”这种情绪化词汇来包裹,试图营造一种人道主义的温情。但如果我们用加尔通的暴力三角去看,这件事的本质是 structural violence 的削减:它直接把“切除膀胱”这个残酷的物理剥夺从治疗路径中剔除了。

切除膀胱不仅仅是手术,它是一次彻底的身体主权丧失。正如 Tracey Emin 所描述的,尿路造口将私密的身体功能强制性地搬到体外,这种状态在文化层面上被定义为“需要保守的秘密”,本质上是对患者主体性的二次羞辱。当一个人必须通过隐藏身体零件来维持“正常人”的表达时,这种差额就是暴力。

这次突破的 anactual 意义在于:通过 immunotherapy 改变了博弈结果,让患者在不牺牲身体完整性的前提下获得了生存权。这不是一种表演性的让步,而是 Actual 真正向 Potential 走近了一步。它削减了患者在面对疾病时必须接受的、由医疗结构强加的身体残缺。

当然,这还不是最终胜利。目前的 trial 只有 54 人,且由 AstraZeneca 这种巨头 funding。在它变成普惠的 standard practice 之前,它依然是一个关于定价权和资源分配的博弈场。我们要警惕的是,这种“更温柔”的方案是否会变成一种昂贵的特权,而让底层患者继续在手术台上被切割。

Many medical reports wrap breakthroughs in emotional terms like "kinder" or "life-changing," attempting to create a narrative of humanitarian warmth. But through the lens of the Violence Triangle, the essence here is the reduction of structural violence: it removes the brutal physical deprivation of "bladder removal" from the treatment path.

Removing the bladder is more than just surgery; it is a total loss of bodily sovereignty. As Tracey Emin described, a urostomy bag forces a private bodily function into the public sphere. In the cultural layer, this is defined as a "secret to be kept," which is essentially a secondary humiliation of the patient's subjectivity. When one must hide a body part to maintain the expression of a "normal person," that gap is violence.

The actual significance of this breakthrough is that immunotherapy has changed the game, allowing patients to survive without sacrificing bodily integrity. This isn't a performative concession; it is the Actual moving closer to the Potential. It carves out a piece of the physical and psychological burden imposed by the medical structure.

Of course, this isn't the final victory. The trial involved only 54 people and was funded by a giant like AstraZeneca. Until this becomes a universal standard practice, it remains a battlefield of pricing power and resource allocation. We must remain vigilant that this "kinder" approach doesn't become an expensive privilege, leaving the marginalized to continue being carved open on the operating table.